tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

MNPR Stock Latest News

MNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
RatingsMNPR: Favorable Risk/Reward on ALXN1840’s Differentiated Profile and De-Risked Regulatory Pathway in Wilson’s Disease
10d ago
MNPR
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Today, 1/30/2026, According to Top Analysts
12d ago
ENGN
MNPR
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
29d ago
CYTK
MNPR
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
PremiumThe Fly
Monopar Therapeutics initiated with an Overweight at Morgan Stanley
1M ago
MNPR
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
PremiumRatings
Monopar Therapeutics: ALXN1840’s Differentiated Efficacy, De‑Risked Profile, and Strong Cash Runway Underpin Overweight/Buy Rating
1M ago
MNPR
Optimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
PremiumRatingsOptimistic Buy Rating for Monopar Therapeutics Inc: Promising ALXN1840 Data and Strong Financial Position
3M ago
MNPR
Monopar downgraded to Outperform from Strong Buy at Raymond James
Premium
The Fly
Monopar downgraded to Outperform from Strong Buy at Raymond James
3M ago
MNPR
Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
Premium
Company Announcements
Monopar Therapeutics Reports Increased Cash Reserves Amid Losses
3M ago
MNPR
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
PremiumThe Fly
Monopar Therapeutics reports Q EPS (48c), consensus (40c)
3M ago
MNPR
Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
PremiumRatings
Promising Potential of Monopar Therapeutics: Buy Rating Backed by ALXN1840’s Efficacy and Safety Data
3M ago
MNPR
Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Coinbase upgraded, Six Flags downgraded: Wall Street’s top analyst calls
3M ago
JD
FUN
Monopar Therapeutics Unveils Promising Phase 2 Study Results
PremiumCompany Announcements
Monopar Therapeutics Unveils Promising Phase 2 Study Results
3M ago
8K
MNPR
Monopar Therapeutics initiated with an Outperform at Leerink
PremiumThe FlyMonopar Therapeutics initiated with an Outperform at Leerink
3M ago
MNPR
Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study
Premium
The Fly
Monopar presents new data, analyses from Phase 2 ALXN1840-WD-204 study
3M ago
MNPR
Monopar Therapeutics Inc (MNPR) Q3 Earnings Cheat Sheet
Premium
Pre-Earnings
Monopar Therapeutics Inc (MNPR) Q3 Earnings Cheat Sheet
3M ago
MNPR
BTIG biotech analyst holds an analyst/industry conference call
PremiumThe Fly
BTIG biotech analyst holds an analyst/industry conference call
4M ago
MNPR
Monopar Therapeutics Advances Cancer Treatment with New Dose-Escalation Study
PremiumCompany Announcements
Monopar Therapeutics Advances Cancer Treatment with New Dose-Escalation Study
4M ago
MNPR
Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications
PremiumCompany Announcements
Monopar Therapeutics’ Innovative Imaging Agent Study: Market Implications
4M ago
MNPR
Monopar Therapeutics initiated with an Overweight at Barclays
PremiumThe Fly
Monopar Therapeutics initiated with an Overweight at Barclays
4M ago
MNPR
Monopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
PremiumRatingsMonopar Therapeutics Inc.: Promising Prospects with ALXN1840 Acquisition and Wilson’s Disease Market Potential
4M ago
MNPR
Monopar Therapeutics price target raised to $142 from $80 at Raymond James
Premium
The Fly
Monopar Therapeutics price target raised to $142 from $80 at Raymond James
4M ago
MNPR
Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer
Premium
The Fly
Monopar Therapeutics price target raised to $115 from $77 at Oppenheimer
4M ago
AZN
MNPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >